|
MechanismNY-ESO-1 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
100 Clinical Results associated with Shenzhen Inno Immunization Co., Ltd
0 Patents (Medical) associated with Shenzhen Inno Immunization Co., Ltd
100 Deals associated with Shenzhen Inno Immunization Co., Ltd
100 Translational Medicine associated with Shenzhen Inno Immunization Co., Ltd